Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Cell and Tissue Acquisition Device Improves Efficiency at More Affordable Price

By BiotechDaily International staff writers
Posted on 26 Feb 2013
Image: Kuiqpick—the new cell and tissue acquisition system from NeuroInDx (Photo courtesy of NeuroInDx).
Image: Kuiqpick—the new cell and tissue acquisition system from NeuroInDx (Photo courtesy of NeuroInDx).
An innovative and affordable new cell and tissue acquisition instrument improves efficiency and ease-of-use compared to existing laser-assisted microdissection systems.

Kuiqpick, introduced by NeuroInDx, Inc. (Los Angeles, CA, USA), is the innovative new laser-assisted microdissection and acquisition system for research laboratories. It includes the additional the capacity to collect cells from tissues and cultures without affecting their viability, enabling the collected cells to then be cultured for further analysis and downstream applications. Also notable, Kuiqpick costs less than USD 30,000 per device, about one-fourth the cost of existing systems. “Kuiqpick [opens] the door for more labs to conduct the critical collection of live cells and tissue areas for examination and culturing,” said Stan Karsten, PhD, NeuroInDx chief scientific officer and cofounder; “For too long, the high cost of tissue microdissection and cell sorting technologies have limited cell-specific research. With the introduction of Kuiqpick, more labs and researchers can afford the technology.”

Rebecca Stockton, PhD, a University of California, Los Angeles (UCLA) assistant professor of pediatrics, uses Kuiqpick to study cerebral cavernous malformations and said, “[Kuiqpick is] perfect for collecting small abnormal blood vessels from the brain tissue and specific cells from cultures based on their form and structure, or their morphology, which is critical for my research.”

Originally conceived at UCLA and further developed by NeuroInDx, Kuiqpick can be attached to an inverted microscope to dissect brain tissue slices at the cellular resolution and collect individual cells from various cell cultures. A single press of a button initiates the collection of the brain tissue area or cells into a disposable capillary unit. Collected tissue samples are then transferred to a test tube for further use. “Kuiqpick is a novel and highly accurate system that has already proven to be extremely efficient in the isolation of specific cell populations from live and freshly frozen brain tissues,” said Dr. Lili C. Kudo, president and CEO of NeuroInDx; “It can be successfully used in a variety of molecular studies, including stem cell research, genomics and proteomics.”

NeuroInDx also offers to provide researchers with custom cell and tissue collection services and subsequent gene expression-microarray experiments, thus saving time and funding for their projects.

Related Links:

NeuroInDx





comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.